Table.
Infant and maternal demographic and delivery characteristics, and maternal HIV virologic and immunologic measures during pregnancy, by cCMV status
| Characteristics | cCMV positive (n = 8) | cCMV negative (n = 887) | Total (N = 895) | P value* |
|---|---|---|---|---|
| Infant characteristics | ||||
| Current age (years) | 7.4 (6.2–8.0) | 5.9 (4.0–7.8) | 5.9 (4.0–7.8) | .11 |
| Birth year | ||||
| 2007–2009 | 4 (50%) | 251 (28%) | 255 | |
| 2010–2012 | 3 (38%) | 339 (38%) | 342 | |
| 2013–2015 | 1 (13%) | 297 (33%) | 298 | |
| Male sex | 4 (50%) | 473 (53%) | 477 (53%) | >.99 |
| Race | ||||
| Black | 6 (75%) | 482 (54%) | 488 (55%) | .54 |
| White | 1 (13%) | 284 (32%) | 285 (32%) | |
| Other/unknown | 1 (13%) | 121 (14%) | 122 (14%) | |
| Hispanic ethnicity | 2 (25%) | 357 (40%) | 359 (40%) | .50 |
| Birth weight (g) | 3087 (2623–3374) | 3030 (2710–3365)† | 3030 (2710–3365)† | .96 |
| Head circumference (cm) | 34.6 (32.8–35.3) | 34.0 (32.7–35.0)‡ | 34.0 (32.7–35.0)‡ | .48 |
| Length (cm) | 50.0(48.4–51.1) | 49.0 (47.2–50.8)§ | 49.0 (47.3–50.8)§ | .30 |
| Gestational age (wk) | 39.6 (38.2–39.9) | 38.3 (37.6–39.3)¶ | 38.3 (37.6–39.3)¶ | .11 |
| Gestational age <37 wk | 0 (0%) | 140 (16%)‡ | 140 (16%)‡ | .62 |
| Maternal characteristics | ||||
| Mother’s age at delivery | 29.0(21.4–31.5) | 29.1 (24.6–33.6)‡ | 29.1 (24.6–33.6)‡ | .48 |
| Cesarean delivery | 3 (38%) | 517(58%)† | 520 (58%)† | .40 |
| Caregiver <HS degree | 1 (25%)† | 190(31%)** | 191 (31%) | >.99 |
| Caregiver household income ≤$20 000 | 3 (75%)† | 452 (77%)†† | 455 (77%) | >.99 |
| Maternal immunologic and HIV virologic measurements (first and last values during pregnancy) and maternal HIV ARV drug regimen during pregnancy | ||||
| First CD4% <20 | 3 (37.5%) | 176 (20.2%)‡‡ | 179 (20.3%)‡‡ | .21 |
| First CD4 <200 cells/mm3 | 1 (12.5%) | 95 (10.8%)§§ | 96 (10.9%)§§ | .60 |
| First RNA >400 copies/mL | 5 (62.5%) | 422 (47.9%)¶¶ | 427 (48.0%)¶¶ | .49 |
| Last CD4% <20 | 3 (37.5%) | 112(12.8%)‡‡ | 115(13.0%)‡‡ | .07 |
| Last CD4 <200 cells/mm3 | 1 (12.5%) | 62 (7.1%)§§ | 63 (7.1%)§§ | .45 |
| Last RNA >400 copies/mL | 2 (25.0%) | 105 (11.9%)¶¶ | 107 (12.0%)¶¶ | .25 |
| ARV pregnancy regimen** | ||||
| cART | 7 (88%) | 802 (90%) | 809 (90%) | .11 |
| Other ARVs | 0 (0%) | 53 (6%) | 53 (6%) | |
| No ARVs | 1 (13%) | 7(1%) | 8(1%) | |
| Unknown | 0 (0%) | 25 (3%) | 25 (3%) | |
| NRTI-unexposed | 1 (13%) | 11 (1%) | 12(1%) | .12 |
| NRTI-exposed | 7 (88%) | 853 (96%) | 860 (96%) | |
| NNRTI-unexposed | 6 (75%) | 707 (80%) | 713(80%) | .71 |
| NNRTI-exposed | 2 (25%) | 157 (18%) | 159 (18%) | |
| Protease inhibitor unexposed | 4 (50%) | 191 (22%) | 195(22%) | .14 |
| Protease inhibitor exposed | 4 (50%) | 673 (76%) | 677 (76%) | |
| Integrase inhibitor unexposed | 7 (88%) | 759 (86%) | 766 (86%) | >.99 |
| Integrase inhibitor exposed | 1 (13%) | 105 (12%) | 106 (12%) | |
| Fusion inhibitor unexposed | 8(100%) | 856 (97%) | 864 (97%) | >.99 |
| Fusion inhibitor exposed | 0 (0%) | 8(1%) | 8(1%) |
NNRTI, non-nucleoside reverse transcriptase inhibitor; NRTI, nucleoside reverse transcriptase inhibitor.
Median with IQRs reported where applicable; numbers with missing values are as follows
4 missing
3 missing
2 missing
8 missing
277 missing
301 missing
14 missing
10 missing
6 missing.
Wilcoxon rank-sum test for continuous variables and Fisher exact test for categorical values.
ARV regimen the mother received during pregnancy. cART was defined as cART consisting of ≥3 ARV drugs from ≥2 different drug classes. Other ARVs were defined as any combination not meeting the definition of cART. ARV drug class exposure at any time during pregnancy is reported for 5 drug classes. ARV drug class data were missing for 23 of the mothers of cCMV-negative participants.